Events Timeline
News
Valuation Metrics



Financials
Trading Trends
People Also Watch
Frequently Asked Questions
What is 89Bio Inc (ETNB) stock price today?
The current price of ETNB is 0 USD — it has increased 0 % in the last trading day.
What is 89Bio Inc (ETNB)'s business?
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
What is the price predicton of ETNB Stock?
Wall Street analysts forecast ETNB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ETNB is28.33 USD with a low forecast of 11.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
What is 89Bio Inc (ETNB)'s revenue for the last quarter?
89Bio Inc revenue for the last quarter amounts to -75.91M USD, increased 32.53 % YoY.
What is 89Bio Inc (ETNB)'s earnings per share (EPS) for the last quarter?
89Bio Inc. EPS for the last quarter amounts to -71809000.00 USD, increased 80.79 % YoY.
How many employees does 89Bio Inc (ETNB). have?
89Bio Inc (ETNB) has 93 emplpoyees as of January 15 2026.
What is 89Bio Inc (ETNB) market cap?
Today ETNB has the market capitalization of 741.82M USD.





